+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic Retinopathy Market - Global Forecast to 2030- Product Image
Diabetic Retinopathy Market - Global Forecast to 2030- Product Image
Sale

Diabetic Retinopathy Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5788863
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diabetic Retinopathy Market grew from USD 9.07 billion in 2024 to USD 9.62 billion in 2025. It is expected to continue growing at a CAGR of 6.21%, reaching USD 13.02 billion by 2030.

Diabetic retinopathy remains a leading cause of vision impairment among working-age adults, challenging healthcare systems and driving innovation across therapeutics, diagnostics, and surgical interventions. Early microvascular changes triggered by chronic hyperglycemia progress from non-proliferative to proliferative stages, increasing the risk of severe vision loss without timely diagnosis and treatment. Advancements in anti-VEGF agents transformed clinical pathways by targeting angiogenic factors, while sustained-release corticosteroid implants and next-generation laser systems further expanded therapeutic options. As patient populations diversify into adult and pediatric cohorts and care settings evolve from clinics to ambulatory surgical centers and hospitals, stakeholders must adapt to emerging segmentation priorities. Concurrently, regional regulations and impending tariff adjustments in the United States are reshaping supply chains and pricing dynamics. This executive summary synthesizes pivotal shifts, segmentation and regional insights, corporate strategies, and actionable recommendations to inform decision-makers navigating this complex landscape.

Transformative Shifts in Therapeutics, Diagnostics, and Care Delivery

The diabetic retinopathy landscape is undergoing transformative shifts driven by technological breakthroughs and evolving care paradigms. Transitioning from traditional grid and focal laser therapies, clinicians now leverage stereotactic precision laser systems integrated with real-time imaging to optimize focal treatment. Innovations in sustained-release corticosteroid implants address inflammation over extended durations, reducing injection frequency and enhancing compliance. Within pharmacotherapy, the emergence of biosimilars for aflibercept and ranibizumab fosters competitive pricing and broader accessibility. Artificial intelligence tools capable of automated retinal image analysis accelerate screening in primary care, enabling earlier detection in non-proliferative stages. These trends are converging toward a personalized care model, where patient type-adult or pediatric-diagnostic severity, and end-user setting-from general clinics to specialty centers and both private and public hospitals-drive tailored treatment algorithms. As value-based care models gain traction, payers and providers are aligning on outcome metrics, reinforcing the shift from volume to value in diabetic retinopathy management.

Analyzing the Cumulative Impact of 2025 United States Tariffs

The introduction of new tariff schedules in 2025 will influence import costs for critical ophthalmic devices and biologics in the United States. Allocations imposed on laser equipment components, surgical implants, and raw materials for corticosteroid and anti-VEGF formulation manufacturing are poised to elevate landed costs. Forward-looking manufacturers are exploring tariff-mitigation strategies, such as near-shoring assembly lines and negotiating binding price escalators with suppliers to preserve margin integrity. Hospitals and ambulatory surgical centers dependent on imported instruments may face increased capital expenditure cycles, while clinics could see incremental price adjustments for in-office injections. Payers are anticipating these shifts by updating reimbursement frameworks, emphasizing domestic sourcing clauses, and incentivizing providers to adopt cost-effective biosimilar agents. Ultimately, stakeholders must navigate a more complex pricing environment where supply chain resiliency, regulatory compliance, and strategic procurement become critical levers for sustaining market access and patient affordability.

Key Segmentation Insights Across Therapeutics, Patients, and Care Settings

Segmenting the diabetic retinopathy market illuminates nuanced growth drivers across therapeutic classes, patient cohorts, disease stages, and care settings. By product type, the landscape encompasses anti-VEGF agents, corticosteroids, laser equipment, and surgical implants. Within anti-VEGF therapies, aflibercept leads with robust real-world outcomes, while bevacizumab maintains off-label cost advantages and ranibizumab benefits from pediatric labeling. Corticosteroids further break down into dexamethasone and triamcinolone implants offering differentiated release profiles. Disease segmentation contrasts non-proliferative retinopathy, where screening tools and earlier interventions dominate, with proliferative presentations that rely on advanced surgical implants and laser strategies. Patient type differentiation between adults and pediatric populations underscores unique diagnostic pathways and dosing regimens. End-user analysis highlights distinct workflows across ambulatory surgical centers, general and specialty clinics, private hospitals, and public hospitals, each balancing capital intensity, procedural volumes, and payer mix. This multi-dimensional segmentation framework enables targeted investment and product development decisions at every stage of the care continuum.

Key Regional Insights Highlighting Growth Drivers and Challenges

Regional dynamics in diabetic retinopathy are shaped by healthcare infrastructure maturity, reimbursement policies, and patient demographics. In the Americas, the United States drives innovation adoption, backed by high per-capita healthcare spend and structured screening initiatives, while Latin American markets focus on expanding clinic networks and negotiating drug prices. Europe, Middle East & Africa exhibit heterogeneous patterns, with Western European countries leveraging reimbursement for advanced biologics, GCC states investing in hospital capacity, and sub-Saharan regions prioritizing cost-effective generics and mobile screening targets. Asia-Pacific presents a spectrum ranging from Japan’s integration of AI diagnostics and premium therapies to Southeast Asian emphasis on biosimilar penetration, and Greater China’s parallel development of home-care models. Strategic partnerships with regional distributors and technology providers are critical for navigating these varied regulatory and economic landscapes, ensuring that innovations in drug delivery and imaging reach diverse patient populations.

Key Company Insights Driving Innovation and Competitive Positioning

Leading pharmaceutical and biotechnology firms shape the competitive landscape through diversified portfolios and pipeline innovation. Major players such as AbbVie Inc., Amgen Inc., Bayer AG, F. Hoffmann-La Roche AG, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, and Eli Lilly and Company command significant market share in anti-VEGF and corticosteroid franchises. Specialist innovators AEYE Health, Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., Ocular Therapeutix, Inc., Ocugen, Inc., Ocuphire Pharma, Inc., Opthea Limited, and Oxurion NV are advancing novel delivery platforms and gene-therapy candidates. Contract manufacturers BCN Peptides, S.A.U., Kodiak Sciences Inc., and Samsung Biologics Co., Ltd. bolster production capacity for peptides and biologics. Diagnostic leaders Eyenuk, Inc., RetinaRisk, and RETMARKER are integrating artificial intelligence into screening, while REGENXBIO Inc. pioneers vector-based approaches. Emerging developers ANI Pharmaceuticals, Inc. and OcuTerra Therapeutics are contributing to niche pipeline assets focused on targeted inflammatory pathways. Bausch + Lomb Corporation continues to innovate optical and surgical technologies, anchoring device portfolios across global markets.

Actionable Recommendations for Industry Leaders to Enhance Market Impact

To capitalize on evolving market dynamics, industry leaders should pursue strategic initiatives that align with segmented needs and regional priorities. First, invest in real-world evidence programs to demonstrate long-term benefits of novel formulations across non-proliferative and proliferative populations, strengthening payer negotiations. Second, establish localized manufacturing hubs or partnerships to offset tariff impacts and streamline distribution in high-growth regions. Third, expand AI-driven screening collaborations with primary care networks to capture early-stage patients, improving referral pathways for specialty clinics and hospitals. Fourth, adopt value-based contracting models tied to patient-reported outcomes, enhancing alignment with payers focused on population health metrics. Fifth, diversify portfolios through co-development agreements with diagnostic and device innovators, enabling integrated care solutions. Finally, prioritize adult-to-pediatric translational research to address under-served pediatric cohorts and secure regulatory designations that facilitate market access.

Conclusion: Synthesizing Insights to Guide Strategic Decision-Making

The diabetic retinopathy landscape is characterized by rapid innovation, multifaceted segmentation, and shifting regulatory levers. Navigating this complexity requires a clear understanding of therapeutic advancements, patient needs, and regional market nuances. Stakeholders who proactively address tariff challenges, optimize segmentation-based strategies, and collaborate across the value chain will secure competitive advantage. Prioritizing evidence-generation, forging strategic manufacturing and distribution alliances, and embracing outcome-oriented reimbursement models will ensure sustainable growth. As the market continues to evolve, integrating diagnostics, therapeutics, and digital health within cohesive care pathways will define the next era of vision preservation, delivering improved outcomes for diverse patient populations.

Market Segmentation & Coverage

This research report categorizes the Diabetic Retinopathy Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Anti-VEGF Agents
    • Aflibercept
    • Bevacizumab
    • Ranibizumab
  • Corticosteroids
    • Dexamethasone
    • Triamcinolone
  • Laser Equipment
  • Surgical Implants
  • Non-Proliferative Diabetic Retinopathy
  • Proliferative Diabetic Retinopathy
  • Adult
  • Pediatric
  • Ambulatory Surgical Centers
  • Clinics
    • General Clinics
    • Specialty Clinics
  • Hospitals
    • Private Hospitals
    • Public Hospitals

This research report categorizes the Diabetic Retinopathy Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Diabetic Retinopathy Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • AEYE Health
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • Bausch + Lomb Corporation
  • Bayer AG
  • BCN Peptides, S.A.U.
  • Boehringer Ingelheim International GmbH
  • Clearside Biomedical, Inc.
  • Eli Lilly and Company
  • Eyenuk, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • Kodiak Sciences Inc.
  • Novartis AG
  • Ocugen, Inc.
  • Ocular Therapeutix, Inc.
  • Ocuphire Pharma, Inc.
  • OcuTerra Therapeutics
  • Opthea Limited
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • REGENXBIO Inc.
  • RetinaRisk
  • RETMARKER
  • Samsung Biologics Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Diabetic Retinopathy Market, by Product Type
8.1. Introduction
8.2. Anti-VEGF Agents
8.2.1. Aflibercept
8.2.2. Bevacizumab
8.2.3. Ranibizumab
8.3. Corticosteroids
8.3.1. Dexamethasone
8.3.2. Triamcinolone
8.4. Laser Equipment
8.5. Surgical Implants
9. Diabetic Retinopathy Market, by Diabetic Type
9.1. Introduction
9.2. Non-Proliferative Diabetic Retinopathy
9.3. Proliferative Diabetic Retinopathy
10. Diabetic Retinopathy Market, by Patient Type
10.1. Introduction
10.2. Adult
10.3. Pediatric
11. Diabetic Retinopathy Market, by End-User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.3.1. General Clinics
11.3.2. Specialty Clinics
11.4. Hospitals
11.4.1. Private Hospitals
11.4.2. Public Hospitals
12. Americas Diabetic Retinopathy Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Diabetic Retinopathy Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Diabetic Retinopathy Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. AEYE Health
15.3.3. Amgen Inc.
15.3.4. ANI Pharmaceuticals, Inc.
15.3.5. Bausch + Lomb Corporation
15.3.6. Bayer AG
15.3.7. BCN Peptides, S.A.U.
15.3.8. Boehringer Ingelheim International GmbH
15.3.9. Clearside Biomedical, Inc.
15.3.10. Eli Lilly and Company
15.3.11. Eyenuk, Inc.
15.3.12. EyePoint Pharmaceuticals, Inc.
15.3.13. F. Hoffmann-La Roche AG
15.3.14. Kodiak Sciences Inc.
15.3.15. Novartis AG
15.3.16. Ocugen, Inc.
15.3.17. Ocular Therapeutix, Inc.
15.3.18. Ocuphire Pharma, Inc.
15.3.19. OcuTerra Therapeutics
15.3.20. Opthea Limited
15.3.21. Oxurion NV
15.3.22. Pfizer, Inc.
15.3.23. Regeneron Pharmaceuticals, Inc.
15.3.24. REGENXBIO Inc.
15.3.25. RetinaRisk
15.3.26. RETMARKER
15.3.27. Samsung Biologics Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DIABETIC RETINOPATHY MARKET MULTI-CURRENCY
FIGURE 2. DIABETIC RETINOPATHY MARKET MULTI-LANGUAGE
FIGURE 3. DIABETIC RETINOPATHY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SURGICAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 59. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 61. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 62. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 63. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 66. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 101. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 103. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 104. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 105. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 108. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 109. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 110. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 111. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 112. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 113. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 116. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 117. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 119. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 120. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 121. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 125. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 127. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 128. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 129. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 130. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 132. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 133. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 135. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 136. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 137. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 141. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 142. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 143. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 144. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 145. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 149. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 150. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 151. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 152. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 153. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 157. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 165. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 167. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 168. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 169. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 173. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 174. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 175. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 176. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 177. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 180. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 181. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 183. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 198. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 199. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 200. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 201. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 202. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 205. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 206. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 208. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 209. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 210. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 213. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 214. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 215. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 216. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 217. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 218. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 222. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 224. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 225. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 226. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 229. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 230. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 232. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 233. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 234. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 235. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 237. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 246. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 248. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 249. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 250. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 251. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 252. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 253. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 254. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 270. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 272. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 273. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 278. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 280. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 281. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 282. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 284. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 285. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 286. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 287. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 288. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 289. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 290. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 292. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 293. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 294. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 296. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 297. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 302. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 318. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 319. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 320. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 321. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 322. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 323. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 324. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 325. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 327. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 328. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 329. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 330. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 331. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 334. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 335. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 336. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 337. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 338. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 339. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 340. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 341. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 342. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 343. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2030 (USD MILLION)
TABLE 344. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 345. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2030 (USD MILLION)
TABLE 346. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY

Companies Mentioned

  • AbbVie Inc.
  • AEYE Health
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • Bausch + Lomb Corporation
  • Bayer AG
  • BCN Peptides, S.A.U.
  • Boehringer Ingelheim International GmbH
  • Clearside Biomedical, Inc.
  • Eli Lilly and Company
  • Eyenuk, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • Kodiak Sciences Inc.
  • Novartis AG
  • Ocugen, Inc.
  • Ocular Therapeutix, Inc.
  • Ocuphire Pharma, Inc.
  • OcuTerra Therapeutics
  • Opthea Limited
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • REGENXBIO Inc.
  • RetinaRisk
  • RETMARKER
  • Samsung Biologics Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • 273 Pages
  • Global
From
Diabetic Retinopathy Treatment Market Report and Forecast 2024-2032 - Product Image

Diabetic Retinopathy Treatment Market Report and Forecast 2024-2032

  • Report
  • 250 Pages
  • Global
From
Proliferative Diabetic Retinopathy (PDR) Market Report 2025 - Product Image

Proliferative Diabetic Retinopathy (PDR) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Non-Proliferative Diabetic Retinopathy Market Report 2025 - Product Image

Non-Proliferative Diabetic Retinopathy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Diabetic Retinopathy Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Diabetic Retinopathy Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 96 Pages
  • Global
From

About the Diabetic Retinopathy Market

Diabetic Retinopathy (DR) is a medical condition that affects the eyes of people with diabetes. It is caused by damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. DR can lead to vision loss and blindness if left untreated. Optical imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are used to diagnose and monitor DR. These technologies allow for early detection and treatment of DR, which can help to reduce the risk of vision loss. In addition to imaging technologies, there are a number of treatments available for DR, including laser photocoagulation, intravitreal injections, and vitrectomy. These treatments can help to reduce the risk of vision loss and improve vision in those with DR. The DR market is a rapidly growing market, driven by the increasing prevalence of diabetes and the need for early detection and treatment of DR. Companies in the DR market include Carl Zeiss Meditec, Topcon Corporation, Optos, Nidek, and Heidelberg Engineering. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.